Earnings Recaps

Browse reported earnings of the most popular stocks

Apr 2, 2026 Apr 1, 2026 Mar 31, 2026 Mar 30, 2026 Mar 26, 2026 Mar 25, 2026 Mar 20, 2026 Mar 19, 2026 Mar 18, 2026 Mar 17, 2026 Mar 16, 2026 Mar 13, 2026 Mar 12, 2026 Mar 11, 2026 Mar 9, 2026 Mar 7, 2026 Mar 6, 2026 Mar 5, 2026 Mar 4, 2026 Mar 3, 2026 Mar 2, 2026 Feb 28, 2026 Feb 27, 2026 Feb 26, 2026 Feb 25, 2026 Feb 24, 2026 Feb 23, 2026 Feb 21, 2026 Feb 20, 2026 Feb 19, 2026 Feb 18, 2026 Feb 17, 2026 Feb 14, 2026 Feb 13, 2026 Feb 12, 2026 Feb 11, 2026 Feb 10, 2026 Feb 9, 2026 Feb 7, 2026 Feb 6, 2026 Feb 5, 2026 Feb 4, 2026 Feb 3, 2026 Feb 2, 2026 Jan 31, 2026 Jan 30, 2026 Jan 29, 2026 Jan 28, 2026 Jan 27, 2026 Jan 26, 2026 Jan 23, 2026 Jan 22, 2026 Jan 21, 2026 Jan 20, 2026 Jan 17, 2026 Jan 16, 2026 Jan 15, 2026 Jan 14, 2026 Jan 9, 2026 Jan 8, 2026 Jan 7, 2026 Jan 6, 2026 Dec 19, 2025 Dec 18, 2025 Dec 17, 2025 Dec 12, 2025 Dec 11, 2025 Dec 10, 2025 Dec 9, 2025 Dec 6, 2025 Dec 5, 2025 Dec 4, 2025 Dec 3, 2025 Dec 2, 2025 Dec 1, 2025 Nov 27, 2025 Nov 26, 2025 Nov 25, 2025 Nov 24, 2025 Nov 23, 2025 Nov 21, 2025 Nov 20, 2025 Nov 19, 2025 Nov 18, 2025 Nov 17, 2025 Nov 15, 2025 Nov 14, 2025 Nov 13, 2025 Nov 12, 2025 Nov 11, 2025 Nov 10, 2025 Nov 9, 2025 Nov 8, 2025 Nov 7, 2025 Nov 6, 2025 Nov 5, 2025 Nov 4, 2025 Nov 1, 2025 Oct 31, 2025 Oct 30, 2025 Oct 29, 2025 Oct 28, 2025 Oct 27, 2025 Oct 25, 2025 Oct 24, 2025 Oct 23, 2025 Oct 22, 2025 Oct 21, 2025 Oct 17, 2025 Oct 16, 2025 Oct 15, 2025 Oct 14, 2025 Oct 9, 2025 Oct 8, 2025 Oct 7, 2025 Sep 25, 2025 Sep 23, 2025 Sep 17, 2025 Sep 16, 2025 Sep 11, 2025 Sep 10, 2025 Sep 9, 2025 Sep 5, 2025 Sep 4, 2025 Sep 3, 2025 Sep 2, 2025 Sep 1, 2025 Aug 28, 2025 Aug 26, 2025 Aug 25, 2025 Aug 22, 2025 Aug 21, 2025 Aug 20, 2025 Aug 19, 2025 Aug 18, 2025 Aug 15, 2025 Aug 14, 2025 Aug 13, 2025 Aug 12, 2025 Aug 11, 2025 Aug 9, 2025 Aug 8, 2025 Aug 2, 2025 Aug 1, 2025 Jul 30, 2025 Jul 29, 2025 Jul 25, 2025
21 companies Today

Analog Devices, Inc.

ADI Q4 2025
Reported: 2025-11-26

Analog Devices (ADI) reported strong fourth-quarter results for fiscal year 2025, with revenue and earnings per share exceeding expectations, driven by robust growth across all end markets and record free cash flow generation.

Key takeaways
  • Revenue and earnings per share grew over 20% in FY '25, surpassing the midpoint of the company’s outlook.
  • Record free cash flow exceeded $4 billion, representing 39% of revenue, with over $4 billion returned to shareholders through dividends and share repurchases.
  • Strong demand in industrial automation, energy, and automotive sectors drove significant growth, with a 20% increase in design pipeline.
  • Investment in R&D reached record levels to enhance capabilities in analog, mixed signal, and power technologies, alongside a strategic push into software and AI.
  • The company foresees continued growth across key sectors, including AI-driven robotics and energy management systems, in fiscal year 2026.

Amentum Holdings, Inc.

AMTM Q4 2025
Reported: 2025-11-26

Amentum delivered strong performance in fiscal year 2025, achieving revenue of $14.4 billion and a 5% increase in adjusted EBITDA, demonstrating effective execution of its growth strategy amidst a competitive landscape.

Key takeaways
  • Revenues rose to $14.4 billion, reflecting pro forma growth of 4% year-over-year.
  • Adjusted EBITDA increased by 5% to $1.1 billion, with adjusted diluted earnings per share up 11% to $2.22.
  • The company secured a book-to-bill ratio of 1.2x for the year and 1.6x for the fourth quarter, with total bookings of $6.4 billion, driving backlog growth to over $47 billion.
  • Amentum showcased strategic wins, including a $4 billion contract with the U.S. Space Force and a $1.8 billion partnership with Sellafield in the U.K.
  • Free cash flow of $516 million supports debt reduction, reducing net leverage to 3.2x.

Anavex Life Sciences Corp.

AVXL Q4 2025
Reported: 2025-11-26

Anavex Life Sciences demonstrated notable progress in its Alzheimer's and other neurological disease treatments during Q4 2025, emphasizing its commitment to innovation despite encountering regulatory challenges in Europe.

Key takeaways
  • Anavex awaits a potential negative opinion from the CHMP regarding its marketing application for blacaramazine, with plans to request a reexamination based on feedback.
  • A recent peer-reviewed publication highlights significant cognitive benefits from blacaramazine in early Alzheimer's disease patients, indicating a robust therapeutic effect compared to control groups.
  • Long-term clinical data shows that patients on blacaramazine experienced significantly less cognitive decline, translating to approximately 17.8 months of prolonged patient independence.
  • The company is actively engaging with U.S. authorities to advance its Alzheimer's program and has initial contact with the FDA regarding future trials.
  • Anavex is expanding its pipeline focus to include potential treatments for Parkinson's disease, Rett syndrome, and fragile X, further diversifying its research endeavors.

Community

See what investors are trading, holding, and sharing

🌐
All
📈
Stock
📊
ETF
🏦
Mutual Fund
🪙
Crypto
💱
Forex
# Asset Price Community % Type Currency Sector
Loading...